Plain-English translation of NCT07207811 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new medicine called can help people with a rare heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). In this condition, abnormal proteins build up in the heart muscle, making it harder for the heart to pump blood. Researchers want to see if this medication can reduce the risk of serious heart problems and death in people living with this condition.
ATTR-CM is a serious and progressive disease that damages the heart, and current treatments are limited. This study exists to find out whether this medication can slow down or prevent the worsening of heart disease in people with this condition.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication or a placebo (inactive treatment) given through an IV (intravenous line). You will continue taking your regular heart medications as prescribed by your doctor. The study will involve regular visits to the research center for check-ups, blood tests, heart imaging, and monitoring — though the exact schedule is not detailed in this summary, typical heart studies of this type last 1–2 years or longer.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United States